

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eugenio A. Cefali

Examiner: S.L. Channavajjala

Serial No.: 08/960,557

Group Art Unit No.: 1615

Filing Date: October 31, 1997

Confirmation No. : 6174

For:

Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions
Having Unique Biopharmaceutical Characteristics

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. Section 1.97 and 1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. Section 1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 C.F.R. Sections 1.97(g)-(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined above by 37 C.F.R. Section 1.56(b) exists.

This Supplemental Information Disclosure Statement is being submitted after the first Office Action on the merits. Authorization is given to charge the \$180.00 fee associated with the filing of this Information Disclosure Statement to deposit account number 04-2223.

DyKEMA GOSSETT PLLC
10 South Wacker Drive, Suite 2300
Chicago, Illinois 60606 USA
(312) 876-1700
(312) 627-2302 (facsimile)
www.dykema.com
ipmail@dykema.com

Date:

Direct telephone calls to:

Respectfully submitted,

/Lisa V. Mueller/

Attorney for Applicant
Registration No. 38,978

January 8, 2008

312.627.2184